Roivant Sciences Ltd. financial data

Symbol
ROIV on Nasdaq
Industry
Pharmaceutical Preparations
Location
7 Th Floor, 50 Broadway, London
State of incorporation
Bermuda
Fiscal year end
March 31
Latest financial report
10-Q - Q4 2024 - Feb 10, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.03K % +77.7%
Quick Ratio 8 %
Debt-to-equity 10.4 % -69%
Return On Equity -1.99 % -101%
Return On Assets -1.81 % -101%
Operating Margin -741 % -111%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 714M shares -11.5%
Common Stock, Shares, Outstanding 720M shares -10.6%
Entity Public Float 8B USD +1697%
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 723M shares -9.73%
Weighted Average Number of Shares Outstanding, Diluted 723M shares -14.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 153M USD +124%
Research and Development Expense 572M USD +19.1%
General and Administrative Expense 142M USD +10.4%
Operating Income (Loss) -1.13B USD -126%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -721M USD -116%
Income Tax Expense (Benefit) -5.58M USD -124%
Net Income (Loss) Attributable to Parent -117M USD -103%
Earnings Per Share, Basic 0.01 USD/shares -99.8%
Earnings Per Share, Diluted 0.02 USD/shares -99.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.99B USD -70.2%
Marketable Securities, Current 3.16B USD
Cash, Cash Equivalents, and Short-term Investments 5.15B USD
Inventory, Net 34M USD +705%
Other Assets, Current 217M USD +60%
Assets, Current 5.36B USD -21.2%
Property, Plant and Equipment, Net 13.6M USD -37.9%
Operating Lease, Right-of-Use Asset 90.9M USD +93.8%
Intangible Assets, Net (Excluding Goodwill) 136M USD -6.23%
Other Assets, Noncurrent 33.9M USD -27.7%
Assets 5.79B USD -20.8%
Accounts Payable, Current 23.7M USD -32.7%
Employee-related Liabilities, Current 39.3M USD -5.14%
Accrued Liabilities, Current 104M USD -14.6%
Liabilities, Current 141M USD -42.2%
Operating Lease, Liability, Noncurrent 90.5M USD +92.3%
Other Liabilities, Noncurrent 307K USD -93.1%
Liabilities 256M USD -64.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 8.06M USD
Retained Earnings (Accumulated Deficit) 460M USD -36.7%
Stockholders' Equity Attributable to Parent 5.19B USD -14.8%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 5.54B USD -15.9%
Liabilities and Equity 5.79B USD -20.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -193M USD +22.8%
Net Cash Provided by (Used in) Financing Activities -661M USD -8935%
Net Cash Provided by (Used in) Investing Activities -965K USD -1019%
Common Stock, Shares Authorized 7B shares 0%
Common Stock, Shares, Issued 720M shares -10.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -857M USD -254%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2B USD -70.1%
Deferred Tax Assets, Valuation Allowance 767M USD +13.7%
Deferred Tax Assets, Gross 785M USD +12.6%
Operating Lease, Liability 57.2M USD -12.3%
Payments to Acquire Property, Plant, and Equipment 965K USD +139%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -80.8M USD -102%
Lessee, Operating Lease, Liability, to be Paid 75.4M USD -22.6%
Operating Lease, Liability, Current 9.84M USD -6.13%
Lessee, Operating Lease, Liability, to be Paid, Year Two 9.66M USD -15.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 10.7M USD -21.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure -12.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 8.85M USD -13.9%
Deferred Tax Assets, Operating Loss Carryforwards 519M USD +22.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 8.87M USD -6.55%
Additional Paid in Capital 4.72B USD -12.4%
Depreciation, Depletion and Amortization 4.88M USD -16.4%
Interest Expense 39.3M USD +14.6%